Invitrogen

MGMT Monoclonal Antibody (MT23.2)

MGMT Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 14

MGMT Antibody (35-7000) in ICC/IF

Immunofluorescence analysis of MGMT (MT23.2) was performed using 70 % confluent log phase MCF7 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with MGMT (MT23.2) Mouse Monoclonal antibody (Product # 35-7000) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Produ... View More

MGMT Antibody in Immunohistochemistry (IHC)

MGMT Antibody in Immunohistochemistry (Paraffin) (IHC (P))

Product Image Gallery

MGMT Antibody — Antibody specificity was demonstrated by siRNA mediated knockdown of target protein. HeLa cells were transfected with MGMT siRNA and loss of signal was observed in Western Blot using Anti-MGMT Monoclonal Antibody (Product # 35-7000). {KD}

Product Details

35-7000

Applications

Tested Dilution

Publications

Western Blot (WB)

2 µg/mL

View 4 publications 4 publications

Immunohistochemistry (IHC)

Assay-dependent

View 6 publications 6 publications

Immunohistochemistry (Paraffin) (IHC (P))

View 5 publications 5 publications

Immunocytochemistry (ICC/IF)

2 µg/mL

View 1 publication 1 publication

Flow Cytometry (Flow)

View 1 publication 1 publication

Miscellaneous PubMed (MISC)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Bacteria, Human, Mouse, Rat

Host/Isotype

Mouse / IgG2b

Class

Monoclonal

Type

Antibody

Clone

MT23.2

Immunogen

Recombinant human MGMT

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.1% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_2533219

Target Information

O6-Methylguanine-DNA Methyltransferase (MGMT) is an important DNA repair protein involved in tumor cell resistance to the cytostatic activity of chemotherapeutic alkylating agents. This protein is also effective in protecting normal cells against the genotoxic and carcinogenic effects of DNA alkylation. The alkylating drug resistance is caused by MGMT's ability to remove DNA alkyl groups introduced in the O6 position of guanine. MGMT is expressed in highly variable amounts, depending upon the cell and tissue type, species, and cellular growth characteristics. In addition, MGMT activity varies among groups of tumors and within a particular type of tumor.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.

Journal of neuro-oncology

Sak M,Zumbar CT,King PD,Li X,Mifsud CS,Usubalieva A,Anderson CD,Chesnick HM,McElroy JP,Chakravarti A,Burton EC,Lehman NL

35-7000 was used in Western Blotting to examine the effects of alisertib on the antiproliferative capabilities of carboplatin and irinotecan in glioblastoma cells.

Sat Jun 01 00:00:00 UTC 2019

Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.

JCI insight

Boyd NH,Walker K,Fried J,Hackney JR,McDonald PC,Benavides GA,Spina R,Audia A,Scott SE,Landis CJ,Tran AN,Bevensee MO,Griguer C,Nozell S,Gillespie GY,Nabors B,Bhat KP,Bar EE,Darley-Usmar V,Xu B,Gordon E,Cooper SJ,Dedhar S,Hjelmeland AB

35-7000 was used in Western Blotting to explore whether SLC-0111 can decrease glioblastoma growth when combined with temozolomide, or influence the percentages of brain tumour-initiating cells after chemotherapy.

Thu Dec 21 00:00:00 UTC 2017

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Neuro-oncology

Jakacki RI,Cohen KJ,Buxton A,Krailo MD,Burger PC,Rosenblum MK,Brat DJ,Hamilton RL,Eckel SP,Zhou T,Lavey RS,Pollack IF

35-7000 was used in immunohistochemistry - paraffin section to analyze the Children's Oncology Group ACNS0423 phase 2 study of concurrent temozolomide and radiotherapy followed by lomustine and temozolomide in treatment of children with high-grade glioma

Sat Oct 01 00:00:00 UTC 2016

Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.

PloS one

Munthe S,Petterson SA,Dahlrot RH,Poulsen FR,Hansen S,Kristensen BW

35-7000 was used in immunohistochemistry - paraffin section to study tumor periphery glioma cells and their stem cell phenotype

Mon Jul 10 00:00:00 UTC 2017

Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung.

Cancer research

Leng S,Wu G,Collins LB,Thomas CL,Tellez CS,Jauregui AR,Picchi MA,Zhang X,Juri DE,Desai D,Amin SG,Crowell RE,Stidley CA,Liu Y,Swenberg JA,Lin Y,Wathelet MG,Gilliland FD,Belinsky SA

35-7000 was used in western blot to show that UBR regulates MGMT homeostasis and DNA repair of alkylated DNA adducts in cells.

Sat Aug 01 00:00:00 UTC 2015

Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.

The Journal of clinical endocrinology and metabolism

Bengtsson D,Schrøder HD,Andersen M,Maiter D,Berinder K,Feldt Rasmussen U,Rasmussen ÅK,Johannsson G,Hoybye C,van der Lely AJ,Petersson M,Ragnarsson O,Burman P

35-7000 was used in immunohistochemistry - paraffin section to discuss the use of temozolomide to treat pituitary tumors

Wed Apr 01 00:00:00 UTC 2015

Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Cell stress & chaperones

Castro GN,Cayado-Gutiérrez N,Zoppino FC,Fanelli MA,Cuello-Carrión FD,Sottile M,Nadin SB,Ciocca DR

35-7000 was used in Immunocytochemistry to study the resistance/susceptibility processes associated to temozolomide treatment.

Sun Mar 01 00:00:00 UTC 2015

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.

Chinese journal of cancer

Qiu ZK,Shen D,Chen YS,Yang QY,Guo CC,Feng BH,Chen ZP

35-7000 was used in western blot to study the role of MGMT in the resistance against temozolomide in glioma stem-like cells.

Sat Feb 01 00:00:00 UTC 2014

Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Clinical cancer research : an official journal of the American Association for Cancer Research

Pietanza MC,Kadota K,Huberman K,Sima CS,Fiore JJ,Sumner DK,Travis WD,Heguy A,Ginsberg MS,Holodny AI,Chan TA,Rizvi NA,Azzoli CG,Riely GJ,Kris MG,Krug LM

35-7000 was used in Immunohistochemistry to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer.

Wed Feb 15 00:00:00 UTC 2012

Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Cell stress & chaperones

Castro GN,Cayado-Gutiérrez N,Moncalero VL,Lima P,De Angelis RL,Chávez V,Cuello-Carrión FD,Ciocca DR

35-7000 was used in immunohistochemistry (paraffin) to examine heat shock proteins in different subtypes of gliomas.

Thu Nov 01 00:00:00 UTC 2012

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

Neuro-oncology

Cohen KJ,Pollack IF,Zhou T,Buxton A,Holmes EJ,Burger PC,Brat DJ,Rosenblum MK,Hamilton RL,Lavey RS,Heideman RL

35-7000 was used in Immunohistochemistry to show that Temozolomide failed to improve outcome in children with high-grade astrocytomas.

Tue Mar 01 00:00:00 UTC 2011

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.

BMC cancer

Brell M,Ibáñez J,Tortosa A

35-7000 was used in flow cytometry and immunohistochemistry to review methods to analyze O6-Methylguanine-DNA methyltransferase

Wed Jan 26 00:00:00 UTC 2011

Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas.

Brain pathology (Zurich, Switzerland)

Horbinski C,Hamilton RL,Lovell C,Burnham J,Pollack IF

35-7000 was used in immunohistochemistry - paraffin section to discuss indicators of tumor aggressiveness for pilocytic astrocytoma

Sat May 01 00:00:00 UTC 2010

Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

Pediatric blood & cancer

Pollack IF,Hamilton RL,Sobol RW,Nikiforova MN,Nikiforov YE,Lyons-Weiler MA,LaFramboise WA,Burger PC,Brat DJ,Rosenblum MK,Gilles FH,Yates AJ,Zhou T,Cohen KJ,Finlay JL,Jakacki RI

35-7000 was used in Immunohistochemistry to show mismatch repair deficiency does not frequently contribute to alkylator resistance in malignant gliomas observed in children.

Wed Dec 01 00:00:00 UTC 2010

Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Cancer letters

Kuester D,El-Rifai W,Peng D,Ruemmele P,Kroeckel I,Peters B,Moskaluk CA,Stolte M,Mönkemüller K,Meyer F,Schulz HU,Hartmann A,Roessner A,Schneider-Stock R

Sun Mar 08 00:00:00 UTC 2009

Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Cancer letters

Kuester D,El-Rifai W,Peng D,Ruemmele P,Kroeckel I,Peters B,Moskaluk CA,Stolte M,Mönkemüller K,Meyer F,Schulz HU,Hartmann A,Roessner A,Schneider-Stock R

Sun Mar 08 00:00:00 UTC 2009

Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Cancer letters

Kuester D,El-Rifai W,Peng D,Ruemmele P,Kroeckel I,Peters B,Moskaluk CA,Stolte M,Mönkemüller K,Meyer F,Schulz HU,Hartmann A,Roessner A,Schneider-Stock R

Sun Mar 08 00:00:00 UTC 2009

Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Cancer letters

Kuester D,El-Rifai W,Peng D,Ruemmele P,Kroeckel I,Peters B,Moskaluk CA,Stolte M,Mönkemüller K,Meyer F,Schulz HU,Hartmann A,Roessner A,Schneider-Stock R

Sun Mar 08 00:00:00 UTC 2009

Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.

Histopathology

Cooper WA,Kohonen-Corish MR,Chan C,Kwun SY,McCaughan B,Kennedy C,Sutherland RL,Lee CS

35-7000 was used in immunohistochemistry - paraffin section to investigate the role of DNA repair proteins and their prognostic significance in non-small-cell lung cancer

Tue Apr 01 00:00:00 UTC 2008

O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pollack IF,Hamilton RL,Sobol RW,Burnham J,Yates AJ,Holmes EJ,Zhou T,Finlay JL

Thu Jul 20 00:00:00 UTC 2006

Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.

International journal of oncology

Schildhaus HU,Kröckel I,Lippert H,Malfertheiner P,Roessner A,Schneider-Stock R

Wed Jun 01 00:00:00 UTC 2005

Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.

International journal of oncology

Schildhaus HU,Kröckel I,Lippert H,Malfertheiner P,Roessner A,Schneider-Stock R

Wed Jun 01 00:00:00 UTC 2005

Bioinformatics

Protein Aliases: 6-O-methylguanine-DNA methyltransferase; methylated DNA protein cysteine methyltransferase; Methylated-DNA--protein-cysteine methyltransferase; methylguanine-DNA methyltransferase; MGMT; O-6-methylguan; O-6-methylguanine-DNA-alkyltransferase; O6-methylguanine-DNA methyltransferase

View more View less

Gene Aliases: MGMT

View more View less

UniProt ID: (Human) P16455

View more View less

Entrez Gene ID: (Human) 4255

View more View less

Function(s)

DNA binding damaged DNA binding methylated-DNA-[protein]-cysteine S-methyltransferase activity calcium ion binding methyltransferase activity DNA-methyltransferase activity

Process(es)

DNA ligation DNA methylation DNA dealkylation involved in DNA repair response to toxic substance cellular response to oxidative stress response to drug negative regulation of apoptotic process regulation of cysteine-type endopeptidase activity involved in apoptotic process response to ethanol response to folic acid mammary gland epithelial cell differentiation cellular response to organic cyclic compound cellular response to ionizing radiation positive regulation of double-strand break repair

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

MGMT Monoclonal Antibody (MT23.2)

MGMT Antibody (35-7000) in ICC/IF

Product Details

35-7000

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

Flow Cytometry (Flow)

Miscellaneous PubMed (MISC)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!